Abstract:Ethnopharmacological relevance Yajieshaba (YJSB), approved by the Yunnan Provincial Food and Drug Administration in 2008, are known for their anti-inflammatory, antiviral, and pro-apoptotic properties, effectively treating Hepatic fibrosis (HF). However, its mechanism of action remains unclear. Aim of the study The objective of this investigation is to explore how YJSB influences the TGF-β1/Smad signaling pathway as a strategy for reducing HF. Methods The establishment of a HF model in mice involved ligation of the common bile duct, followed by administration of YJSB. Body and liver weights were measured, and the liver index calculated. Serum levels of ALT, AST, ALP, TBA, and TBIL were assessed using colorimetric methods. Additionally, liver homogenates were analyzed for PIIINP, Col-IV, LN, HA, and Hyp, as well as TGF-β1 activity, using ELISA. Histological analyses of liver sections, stained with H&E, Ag, and Masson's trichrome, were performed to examine inflammation and the accumulation of collagen and reticular fibers. These studies aimed to elucidate the pharmacodynamic effects of YJSB on HF in mice with bile duct obstruction. The target pathways of YJSB were preliminarily identified through immunofluorescence detection of TGF-β1, P-Smad2L, P-Smad2C, P-Smad3L, P-Smad3C, and Smad4 proteins. In vitro experiments included the induction of hepatic stellate cell (HSC-T6) activation by H 2 O 2 . A cell injury model was established for HSC-T6, and the CCK-8 assay was used to determine the optimal YJSB concentration and treatment duration. After pirfenidone (PFD) administration, which inhibits the TGF-β1/Smad pathway, the effects of YJSB on HSC-T6 cell proliferation were observed. ELISA assays quantified Col-III, α-SMA, and Col-I in cell lysates to assess YJSB's impact on collagen synthesis in HSC-T6 cells. Western blot analysis was performed to assess the protein levels within the TGF-β1/Smad signaling cascade. Results In the HF mouse model, administration of YJSB notably augmented the body weight and reduced the liver index. Concurrently, there was an elevation in serum concentrations of ALP, AST, ALT, TBA, and TBIL. Similarly, in the liver homogenates of HF mice, increases were observed in the levels of HA, PIIINP, Col-IV, LN, Hyp, and TGF-β1. Histological assessments using H&E, Ag, and Masson stains indicated a substantial diminution in liver tissue damage. Through immunofluorescence analysis, it was discerned that YJSB modulated the expression of TGF-β1, P-Smad2L, P-Smad2C, and P-Smad3L downwards, while elevating P-Smad3C and Smad4 protein expressions. Additional investigations revealed a significant reduction in α-SMA, Col-I, and Col-III levels in cell culture fluids, suggesting a decrease in collagen synthesis and a protective role against cellular damage. Western blot analyses demonstrated that the TGF-β1/Smad pathway inhibitor, PFD, acted in synergy with YJSB, enhancing its regulatory effects on this pathway, decreasing levels of TGF-β1, P-Smad2L, P-Smad2C, P-Smad3L, and promoting the expression of P-Smad3C. Conclusions YJSB demonstrates a pharmacodynamic effect against HF, enhancing liver functionality and effectively mitigating the damage associated with bile duct obstruction. The proposed action mechanism of YJSB involves modulation of the TGF-β1/Smad signaling pathway. Research indicates that YJSB might play a role in suppressing the movement, programmed cell death, and activation of HSC-T6, potentially decelerating the advancement of hepatic fibrosis.

Therapeutic effect of Haobieyangyinruanjianfang on the mouse liver fibrosis caused by schistosomiasis

Effect of Recombinant Interferon-γ Combined with Anluohuaxianwan on Expression of TIMP-1 and TGF-β1,mRNA in Hepatic Fibrosis of Mice Infected with Schistosoma Japonica

Effect of Anluohuaxian Tablet Combined with Γ-Ifn on Schistosomal Liver Fibrosis

Effect of hepatocyte damage in hepatic fibrogenesis of patients infected with Schistosoma japonicum

In vivo Therapeutic Effects and Mechanisms of Hydroxyasiaticoside Combined With Praziquantel in the Treatment of Schistosomiasis Induced Hepatic Fibrosis

[Expression of Smad Proteins in the Process of Liver Fibrosis in Mice Infected with Schistosoma Japonicum].

Effects of IL-18 on immunoregulation in mice infected with Schistosoma japonica following praziquantel treatment

IFN‐γ Gene Therapy by Intrasplenic Hepatocyte Transplantation: a Novel Strategy for Reversing Hepatic Fibrosis in Schistosoma Japonicum‐infected Mice

The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis.

Determination of Serum Levels of YKL-40 and Hyaluronic Acid in Patients with Hepatic Fibrosis Due to Schistosomiasis Japonica and Appraisal of Their Clinical Value.

Study on the efficacy of IFN-γ gene-modified murine hepatocytes against hepatic fibrosis in Schistosomiasis japonica

The change of the hepatic fibrosis and pigment deposition in mice schistosomal liver fibrosis treated with combination of Anluohuaxian pilule and interferon-γ

Influence of Interferon-Γ Treatment on Smads Expression in Liver Fibrosis of Mice Induced by Schistosoma Japonica

Experimental study on H 2 O 2 activation of HSC-T6 and hepatic fibrosis in cholestatic mice by "Yajieshaba"

Total flavonoids of litchi Seed alleviates schistosomiasis liver fibrosis in mice by suppressing hepatic stellate cells activation and modulating the gut microbiomes

JQ-1 ameliorates schistosomiasis liver fibrosis by suppressing JAK2 and STAT3 activation

Changes of Ultrasonography and Two Serum Biochemical Indices for Hepatic Fibrosis in Schistosomiasis Japonica Patients One Year after Praziquantel Treatment

Dynamic changes of liver sinusoid in BALB/c mice infected with Schistosoma japonicum

Effect of Acarbose on the 24-Hour Blood Glucose Profile and Pattern of Carbohydrate Absorption

NLRP3 inflammasome inhibition decreases Schistosomiasis japonica-induced granulomatous inflammation and fibrosis in BALB/c mice

Inhibition of Rho-Kinase Downregulates Th17 Cells and Ameliorates Hepatic Fibrosis by Schistosoma japonicum Infection